Individuals with mutations in the superoxide dismutase 1 (SOD1) gene develop brain white matter abnormalities before the onset of symptoms of amyotrophic lateral sclerosis (ALS), according to a new imaging study that was presented here at the AAN Annual Meeting in April. Surprisingly, the changes are in a non-motor area of the brain, leaving researchers to wonder whether they signify a previously unsuspected site of disease onset, or a change with no necessary pathogenic relation to the future neurodegenerative process expected in these individuals.
Share this Video
Related Videos In Neuromuscular Diseases
Francesco Saccà, EAN 2022: Improving quality of life for patients with generalized myasthenia gravis – ADAPT trial findings
The ADAPT trial (NCT03669588) supported US Food and Drug Administration approval of efgartigimod alfa-fcab in generalized myasthenia gravis. Dr Francesco Saccà (University of Naples Federico II, Naples, Italy) discussed the findings of the study, in terms of health-related quality-of-life outcomes. Questions: 1. What are the current challenges in managing cases of generalized myasthenia gravis? (00:14) […]
James Howard AAN 2022: Ravulizumab for adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis – Results from the phase 3 CHAMPION-MG OLE trial
Ravulizumab has recently been approved by in the US for the treatment of adults with anti-acetylcholine receptor antibody-positive (AChR Ab+) generalized myasthenia gravis (gMG). Prof. James Howard (The University of North Carolina at Chapel Hill, NC, USA) kindly joins touchNEUROLOGY to discuss the phase 3 CHAMPION-MG trial open label extension study that evaluated the efficacy and […]
James Howard, AAN 2022: Unmet needs in the treatment of myasthenia gravis
Myasthenia gravis (MG) is a rare autoimmune disorder caused by antibodies that act against the myoneural junction, resulting in weakness of the skeletal muscles. Prof. James Howard (The University of North Carolina at Chapel Hill, CA, USA) discusses the unmet needs in the treatment of this rare disease, including, quality of life of patients, response to […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!